Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Cerebrovascular Reactivity in Post-Concussion Syndrome
NCT03417492Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Mar 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sildenafil in Post-concussion syndrome (PCS), sponsored by University of Pennsylvania. Primary endpoint: Global blood oxygen level-dependent (BOLD) response to hypercapnia. Started Mar 2018; status: terminated.
02
Drugs
sildenafil
03
Conditions
Post-concussion syndrome (PCS)
Beyond the preview
Go deeper on NCT03417492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417492.